These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8877730)

  • 21. ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter.
    Thomas RS; Tymms MJ; McKinlay LH; Shannon MF; Seth A; Kola I
    Oncogene; 1997 Jun; 14(23):2845-55. PubMed ID: 9190901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of cytokine gene expression in T helper cell subsets.
    Lederer JA; Liou JS; Todd MD; Glimcher LH; Lichtman AH
    J Immunol; 1994 Jan; 152(1):77-86. PubMed ID: 8254209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sublethal levels of oxidative stress stimulate transcriptional activation of c-jun and suppress IL-2 promoter activation in Jurkat T cells.
    Beiqing L; Chen M; Whisler RL
    J Immunol; 1996 Jul; 157(1):160-9. PubMed ID: 8683110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative regulation of bcl-2 expression by p53 in hematopoietic cells.
    Wu Y; Mehew JW; Heckman CA; Arcinas M; Boxer LM
    Oncogene; 2001 Jan; 20(2):240-51. PubMed ID: 11313951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor.
    Bamberger CM; Else T; Bamberger AM; Beil FU; Schulte HM
    Mol Cell Endocrinol; 1997 Dec; 136(1):23-8. PubMed ID: 9510064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the human interleukin-5 gene promoter: involvement of octamer binding sites in the gene promoter activity.
    Gruart-Gouilleux V; Engels P; Sullivan M
    Eur J Immunol; 1995 May; 25(5):1431-5. PubMed ID: 7774647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53.
    Iotsova V; Crépieux P; Montpellier C; Laudet V; Stehelin D
    Oncogene; 1996 Dec; 13(11):2331-7. PubMed ID: 8957074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter.
    Chuvpilo S; Schomberg C; Gerwig R; Heinfling A; Reeves R; Grummt F; Serfling E
    Nucleic Acids Res; 1993 Dec; 21(24):5694-704. PubMed ID: 8284217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells.
    Novak TJ; Rothenberg EV
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9353-7. PubMed ID: 2174560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive and negative regulation of IL-2 gene expression: role of multiple regulatory sites.
    Zhang L; Nabel GJ
    Cytokine; 1994 May; 6(3):221-8. PubMed ID: 8054477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I.
    Siekevitz M; Feinberg MB; Holbrook N; Wong-Staal F; Greene WC
    Proc Natl Acad Sci U S A; 1987 Aug; 84(15):5389-93. PubMed ID: 3037548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.
    Deb S; Jackson CT; Subler MA; Martin DW
    J Virol; 1992 Oct; 66(10):6164-70. PubMed ID: 1356162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a novel negative regulatory element in the human interleukin 4 promoter.
    Georas S; Cumberland J; Burke T; Park E; Ono S; Casolaro V
    Leukemia; 2000 Apr; 14(4):629-35. PubMed ID: 10764148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive IL-8 expression in cancer cells is associated with mutation of p53.
    Hidaka H; Ishiko T; Ishikawa S; Ikeda O; Mita S; Iwamura T; Chijiiwa K; Ogawa M
    J Exp Clin Cancer Res; 2005 Mar; 24(1):127-33. PubMed ID: 15945132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-regulation of T cell growth factor expression by p53 and the Tax oncogene.
    Chaudhry S; Freebern WJ; Smith JL; Butscher WG; Haggerty CM; Gardner K
    J Immunol; 2002 Dec; 169(12):6767-78. PubMed ID: 12471108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor.
    Wang Q; Zambetti GP; Suttle DP
    Mol Cell Biol; 1997 Jan; 17(1):389-97. PubMed ID: 8972219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of interleukin-6-induced plasma protein secretion in hepatoma cells by p53 species.
    Wang L; Rayanade RJ; Garcia D; Patel K; Pan H; Sehgal PB
    J Biol Chem; 1995 Sep; 270(39):23159-65. PubMed ID: 7559462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species.
    Margulies L; Sehgal PB
    J Biol Chem; 1993 Jul; 268(20):15096-100. PubMed ID: 8325885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positive Regulation of Interleukin-2 Expression by a Pseudokinase, Tribbles 1, in Activated T Cells.
    Miyajima C; Itoh Y; Inoue Y; Hayashi H
    Biol Pharm Bull; 2015; 38(8):1126-33. PubMed ID: 26235576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.